Entering text into the input field will update the search result below

Emergent Bio buys anthrax biologic raxibacumab from Glaxo for up to $96M

Jul. 19, 2017 4:45 PM ETEmergent BioSolutions Inc. (EBS) StockBy: Douglas W. House, SA News Editor4 Comments
  • Emergent Biosystems (NYSE:EBS) inks an agreement with GlaxoSmithKline (GSK) to acquire raxibacumab, a fully human monoclonal antibody for the treatment and prevention of inhaled anthrax, for $76M in upfront cash and up to $20M in milestones.
  • EBS will also assume responsibility for a multiyear contract with BARDA to supply the product to the U.S. Strategic National Stockpile. The value of the contract is ~$130M. It will transfer manufacturing to its Baltimore, MD facilities sometime in 2020.
  • Shares are off a fraction after hours on light volume.

Recommended For You

About EBS Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
EBS--
Emergent BioSolutions Inc.